<DOC>
	<DOC>NCT02141438</DOC>
	<brief_summary>Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.</brief_summary>
	<brief_title>Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Treatment decision to Radium223 needs to be made independent from and before patient enrollment in the study Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases Signed informed consent Previously treated with Radium223 for any reason Currently treated in clinical trials including other Radium223 studies Planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radium-223</keyword>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Phase IV</keyword>
	<keyword>Safety study</keyword>
</DOC>